Capstone Investment Advisors
ACAD icon

Capstone Investment Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Capstone Investment Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$467K Sell
18,442
-4,293
-19% -$94.5K ﹤0.01% 1271
2026
Q1 		$506K Buy
+22,735
New +$543K ﹤0.01% 1131
2024
Q2 		– Sell
-11,403
Closed -$211K – 2037
2024
Q1 		$211K Buy
+11,403
New +$283K ﹤0.01% 1998

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Capstone Investment Advisors's ACAD Position: Q2 2026 in Review

Capstone Investment Advisors reduced its Acadia Pharmaceuticals (ACAD) stake by 19% in Q2 2026, selling an estimated $94.5K and leaving 18,442 shares worth $467K. The position accounts for ﹤0.01% of the portfolio, ranked #1271.

Capstone Investment Advisors first reported a position in ACAD in Q1 2024 and has held it in 3 quarters since. The position peaked at $506K in Q1 2026. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Capstone Investment Advisors held 18,442 shares of Acadia Pharmaceuticals worth $467K as of Q2 2026.
  • Capstone Investment Advisors sold 4,293 Acadia Pharmaceuticals shares in Q2 2026, an estimated $94.5K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1271 holding.
  • Capstone Investment Advisors first reported a position in Acadia Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • Capstone Investment Advisors's Acadia Pharmaceuticals position peaked at $506K in Q1 2026.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.